I think they said something about ovation pursuing Atryn in Canada but I guess that would be after US approval. But that presumably might not require a new trial?
So basically a few million dollars from LFB in 2008 took GTCB's ownership of the collaboration products from average of 50% to average of 13% (per the 10Q) but wasn't enough to keep the projects on schedule.
Just seems to me like other actions by management could have generated small but real amounts of cash (layoffs, salary cuts, maybe find a way to sell merrimack stake or protexia royalty stream)
Market Data 
Markets 
AI
